Pell Bio Med Technology Co Ltd
TWSE:6949
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W
|
Wanxiang Doneed Co Ltd
SSE:600371
|
CN |
|
G
|
General Mills Inc
XETRA:GRM
|
US |
|
Chuo Warehouse Co Ltd
TSE:9319
|
JP |
Pell Bio Med Technology Co Ltd
Total Liabilities
Pell Bio Med Technology Co Ltd
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pell Bio Med Technology Co Ltd
TWSE:6949
|
Total Liabilities
NT$690.3m
|
CAGR 3-Years
42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
GenMont Biotech Inc
TWSE:3164
|
Total Liabilities
NT$334.2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
|
Adimmune Corp
TWSE:4142
|
Total Liabilities
NT$3.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
|
E
|
Energenesis Biomedical Co Ltd
TWSE:6657
|
Total Liabilities
NT$52.7m
|
CAGR 3-Years
23%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Kim Forest Enterprise Co Ltd
TWSE:6645
|
Total Liabilities
NT$526.9m
|
CAGR 3-Years
26%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
Pell Bio Med Technology Co Ltd
Glance View
Pell Bio-Med Technology Co., Ltd. operates as a biotechnology company. The company is headquartered in Taipei City, Taipei. The company went IPO on 2024-03-08. The main business focuses on immune cell therapy that uses genetic engineering to modify the patient's own immune cells. The firm is engaged in the development of chimeric antigen receptor T cell therapy for the treatment of B-cell lymphoma PL001. Non-genetically modified cell therapy products include cytokine-induced killer cells (CIK), and mixed cells using a combination of dendritic cells and cytokine-induced killer cells (DC-CIK). Non-cell products include hair care products and others.
See Also
What is Pell Bio Med Technology Co Ltd's Total Liabilities?
Total Liabilities
690.3m
TWD
Based on the financial report for Dec 31, 2025, Pell Bio Med Technology Co Ltd's Total Liabilities amounts to 690.3m TWD.
What is Pell Bio Med Technology Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 3Y
42%
Over the last year, the Total Liabilities growth was 22%. The average annual Total Liabilities growth rates for Pell Bio Med Technology Co Ltd have been 42% over the past three years .
